SCP
HARP

Sender Company & Partners’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Sender Company & Partners’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,425
Closed -$108K – 116
2021
Q4 		$108K Buy
+1,425
New +$97.2K 0.06% 95

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Sender Company & Partners's HARP Position: Q1 2022 in Review

Sender Company & Partners sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2022, closing a stake of 1,425 shares — an estimated $108K sold.

Sender Company & Partners first reported a position in HARP in Q4 2021 and held it in 1 quarter. The position peaked at $108K in Q4 2021. 79 funds tracked by Wall St. Rank hold HARP as of Q1 2022.

  • Sender Company & Partners reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 1,425 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $108K.
  • Sender Company & Partners first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Harpoon Therapeutics, Inc. Common Stock position peaked at $108K in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.